What are Dexlansoprazole EC Pellets 8.5% W/W?

Dexlansoprazole EC Pellets 8.5% W/W are pharmaceutical pellets specified to contain dexlansoprazole at a drug loading of 8.5% w/w. The EC designation generally refers to enteric coating, which is designed to protect the formulation from acidic gastric conditions. The precise coating system, release profile, and intended finished dosage form must be confirmed against the supplier’s technical documentation.

Uses / Applications

Dexlansoprazole is a proton pump inhibitor (PPI) used in finished medicines to reduce gastric acid production.

Potential applications of dexlansoprazole pellets include:

• Pharmaceutical formulation development.

• Use as an intermediate in suitable oral dosage forms.

• Further processing by qualified pharmaceutical manufacturers, subject to technical suitability.

• Development of formulations requiring an appropriate enteric protection system, if confirmed by the approved product specification.

The suitability of these pellets for a specific finished dosage form should be established through supplier documentation and formulation assessment.

6. Benefits

• Specified drug loading: Identified as 8.5% w/w dexlansoprazole.

• Pellet-based formulation: Provides an intermediate for further pharmaceutical processing.

• Enteric-coating designation: EC indicates an enteric-coated product, subject to confirmation of the actual coating and release specifications.

• Technical information: Product documentation may be requested from the supplier.

• Sourcing support: Kelar Pharmachem India supports pharmaceutical sourcing and export requirements.

Actual product performance depends on the pellet composition, coating characteristics, manufacturing process, and quality specifications.

7. Side Effects

Side effects associated with dexlansoprazole-containing finished medicines may include:

• Diarrhoea

• Abdominal pain

• Nausea

• Vomiting

• Flatulence

Other adverse effects may occur depending on the patient and duration of treatment. Consult the approved prescribing information for the finished medicine for a complete safety profile.

These are potential effects of the active ingredient in a finished medicine, not instructions for direct use of the pharmaceutical pellets.

8. How Does It Work?

Dexlansoprazole suppresses gastric acid secretion by inhibiting the gastric proton pump, an enzyme system involved in the final stage of acid production in the stomach.

The EC designation generally indicates enteric coating intended to protect the formulation from stomach acid and support the specified release behaviour. The exact release mechanism and performance of these particular pellets must be verified using supplier documentation and relevant quality-control data.

9. Dosage Guidelines / Processing Instructions

These pellets are a pharmaceutical intermediate and should not be assumed suitable for direct administration.

• Verify the stated 8.5% w/w drug loading and assay basis.

• Confirm the enteric-coating composition and intended release characteristics.

• Assess compatibility with excipients and the intended finished dosage form.

• Evaluate dissolution, stability, content uniformity, and other applicable quality attributes.

• Follow validated manufacturing procedures and the approved product specification.

The final dosage and administration instructions must be established for the finished medicine in accordance with its approved product information.

10. When Not to Use

For the finished medicine, dexlansoprazole may be unsuitable for individuals with a known hypersensitivity to dexlansoprazole or relevant substituted benzimidazole compounds, or to any ingredient in the finished formulation. The approved product information should be consulted for specific contraindications.

For manufacturing purposes, do not use pellets if their identity, quality status, storage history, or suitability for the intended application cannot be verified.

11. Drug / Product Interactions

Dexlansoprazole-containing medicines may interact with certain medicines or affect the absorption of products whose uptake depends on stomach acidity. Potential interactions can be clinically significant and should be assessed using the approved prescribing information for the finished medicine.

During formulation development, assess compatibility with other active ingredients, excipients, coating materials, and processing conditions. Do not assume compatibility without supporting technical data.

12. Safety Advice

• Handle the pellets according to supplier documentation and applicable site procedures.

• Apply suitable protective measures based on the material safety assessment.

• Avoid generating or inhaling dust during handling, where applicable.

• Maintain batch identification and traceability.

• Review available technical and safety documentation before processing.

• Confirm that the finished product complies with the quality and regulatory requirements applicable to its intended market.

13. General Instructions

• Verify the active ingredient and 8.5% w/w loading against the batch documentation.

• Confirm the EC designation and release profile with the supplier.

• Use the pellets only within an appropriate pharmaceutical manufacturing process.

• Assess stability, coating integrity, and compatibility during formulation development.

• Request additional technical documentation where required for quality assessment.

14. Special Dietary / Lifestyle Tips

Dietary and lifestyle advice applies to patients taking the finished medicine, not to the pharmaceutical pellets themselves.

Depending on the underlying condition, a healthcare professional may recommend individual adjustments to eating habits or other lifestyle measures. Patients should follow the finished medicine’s approved instructions and seek professional advice if symptoms persist or worsen.

15. Comparison with Other Formulations

These formulations are not automatically interchangeable. Selection depends on the intended dosage form, approved specifications, stability, release performance, and manufacturing requirements.

16. Precautions & Warnings

• Confirm that the 8.5% w/w value represents the intended drug-loading specification.

• Verify the meaning of EC and the actual enteric-coating characteristics.

• Do not assume a particular coating polymer, pellet size, dissolution profile, or release mechanism without documentation.

• Evaluate the effect of processing conditions on coating integrity and product stability.

• Confirm suitability for the intended finished dosage form and destination market.

• Avoid unverified claims about regulatory approvals, certifications, or manufacturing compliance.

17. Can I Use It With Other Medicines or Ingredients?

The pellets may be considered for combination formulations only after an appropriate technical assessment. Compatibility studies should address chemical stability, physical properties, processing behaviour, coating integrity, and the desired release profile.

For patient treatment, only a properly manufactured finished medicine should be used according to its approved product information and professional guidance. The pellets should not be combined with medicines for self-administration.

18. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

19. FAQs

Q1. What are Dexlansoprazole EC Pellets 8.5% W/W?

They are pharmaceutical pellets specified to contain dexlansoprazole at a drug loading of 8.5% w/w.

Q2. What does EC mean?

EC generally means enteric-coated. The exact coating system and release characteristics should be confirmed using the supplier’s technical documentation.

Q3. What does 8.5% w/w mean?

It indicates a stated weight-by-weight proportion of 8.5% dexlansoprazole. The assay basis should be verified against the product specification.

Q4. What is dexlansoprazole used for?

Dexlansoprazole is a proton pump inhibitor used in finished medicines to reduce stomach acid production.

Q5. Are these pellets a finished medicine?

The product name identifies pharmaceutical pellets, not a finished patient-ready dosage form. Their intended application should be confirmed with the supplier.

Q6. Is technical documentation available?

Technical data sheets and further product information are available upon request, subject to supplier availability.

Q7. What packing options are available?

Packing details are available on request and should be confirmed against the supplier’s available options and customer requirements.

Q8. What storage conditions are required?

Follow the manufacturer’s approved product specifications and technical documentation. Confirm the exact conditions from the applicable technical data sheet or packaging.